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Abstract
Background: Simkania negevensis is an obligate intracellular bacterium belonging to the family Simkaniaceae in the
Chlamydiales order. It is considered an ubiquitous microorganism and aquatic environments may be involved as a
source of infection for humans. It was just isolated in samples from domestic water supplies and from mains water
supplies, like spa water or swimming pool water, confirming its ability to resist to the common chlorination treatments.
Evidence indicates a possible role of the microorganism in respiratory tract infections, in gastroenteric disorders and in
the pathogenesis of cardiovascular disease, furthermore it has hypothesized that it could play a role in lung transplant
rejection. Prevalence and possible effects in nephrology are unknown.
Methods: We examined the occurrence of Simkania negevensis in two differents populations, both characterized by a
high susceptibility to infectious complications: 105 hemodialysis patients, 105 renal transplant recipients and 105 healthy
subjects through the IgG and IgA response to Simkania negevensis in their sera. Serum antibodies to Simkania negevensis
were detected by a homemade ELISA performed according to the Kahane’s protocol. Furthermore water samples from
hemodialytic circuit were collected, to evaluate Simkania negevensis resistance to usual treatment of disinfection.
Results: Our results were unexpected, showing a higher seroprevalence of antibodies against Simkania negevensis in the
hemodialysis patients, compared to renal transplant patients (IgG 22% vs 9% - IgA 9% vs 3%). S. negevensis was isolated in
all water samples analyzed.
Conclusions: Our study detected for the first time the occurrence of S. negevensis in hemodialysis and in renal transplant
patients. Our findings suggest that water used in hemodialysis could be one of the possible sources of S. negevensis
infection, without clinical involvement risk for patients.
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Background
Chronic kidney disease (CKD) has been recognized
worldwide public health problem, and the associated
morbidity and mortality in patients reaching end-stage
renal disease (ESRD) is constantly increasing [1, 2]. Des-
pite the significant improvements and advanced dialysis
technology [3–5], renal transplantation still remains the
treatment of choice for end stage renal disease patients,
and over the past decades the overall survival rate of
kidney grafts has improved consistently. Moreover, be-
cause of the wide gap between organ supply and de-
mand, there is a growing number of patients with kidney
failure who inexorably accumulate on renal transplant
waiting lists [6], as well as the number of renal trans-
plant (RT) recipients with functioning grafts going to be
exposed to pathogens [7]. Because of immunosuppres-
sive therapy, infections frequently occur after kidney
transplantation with greatly impact on patient morbidity
and mortality. This could explain that infections are the
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second cause of death in renal transplant recipients, fol-
lowing cardiovascular diseases [8]. It is associated with
an increased risk of acute cellular rejection and loss of
graft function [9]. The most common infections are due
to bacteria and viruses, with increasing number of para-
sitic infections in the last years. Infection is a common
complication of hemodialytic treatment too. It has been
identified as the second cause of death also among
hemodialysis (HD) patients and hospitalization for infec-
tion in the HD population has increased in the last de-
cades (2). Many of these infections are due to sepsis
primarily arising from the vascular access site. Simkania
negevensis (S. negevensis) is an obligate intracellular bac-
terium belonging to the family Simkaniaceae in the
Chlamydiales order, able to survive and grow as an
amoeba resisting microorganism in trophozoites and
cysts of Acanthamoeba and other free living protozoa,
which probably represent its natural reservoirs. S. nege-
vensis was first defined in 1993 [10]. It was found that
not only the organism was able to replicate in Acanth-
amoeba, but it was also able to survive over long periods
in amoebal cysts. Since free-living amoebae such as
Acanthamoebae may be found in many water sources, it
may be that the natural source of transmission of S.
negevensis to man is via such amoebae. A widespread
human exposure to S. negevensis has been reported in
epidemiologic studies both in healthy subjects and in as-
sociation with bronchiolitis in infants, both as commu-
nity acquired pneumonia and as acute exacerbation of
chronic obstructive pulmonary disease in adults [11–13].
However diagnostic tools developed during the last dec-
ade will contribute to better understand more precise
epidemiology and pathogenic role in pneumonia and
other clinical contexts, but also to a better understand-
ing about its distribution among healthy subjects. The
seropositivity to S. negevensis in healthy population
groups suggested the organism is a simple colonizer.
However, in vitro studies have shown that S. negevensis
can infect human cell cultures of various tissue origins,
such as respiratory epithelial cells, gastrointestinal tract,
genital tract and endothelial cells [14]. Because of a pos-
sible role as new pathogenic agent of lower respiratory
tract infection, it was investigated among specifically im-
munocompromised hosts, and it was demostrated that
S. negevensis is most prevalent in lung transplant recipi-
ents [15]. The prevalence and pathogenic potential role
of S. negevensis in RT recipients and in HD patients is
still unknown. In this prospective study we proposed to
analyze the S. negevensis occurrence in HD and RT pa-
tients, through IgG and IgA response to S. negevensis in
blood simple: IgA are antibodies produced by the im-
mune system in the first phase of the infection or during
any episodes of reactivation while IgG are “memory”
antibodies, which appear later and remain circulating in
the blood for all life from the first contact with S. nege-
vensis. This investigation was prompted by previous S.
negevensis detection in water sources and by its relatively
resistance to chlorination procedures used for routine
treatment of drinking water supplies [16] and Spa swim-
ming water [17]: water samples were collected from HD
course to evaluate S. negevensis resistance to the purify-
ing treatment commonly performed for HD fluid.
Methods
Population
A total of 315 subjects were enrolled during 2013. The
informed written consent was obtained from all subjects.
At samples collection, RT and HD patients have been
interviewed regarding respiratory symptoms and/or
gastroenteric disorders; furthermore they were moni-
tored about cardiovascular events for a follow up time of
2 years.
Renal transplant patients
105 RT patients, treated at Nephrology, Dialysis and
Kidney Transplantation Unit S. Orsola - Malpighi
University Hospital (Bologna, Italy) after performing
kidney transplantation, were enrolled. The mean age
was 52 years (ranging from 28 to 77 years); the mean
period after transplantation was 7 years (ranging from
1 to 30 years) and the mean glomerular filtration rate
was 54,6 ml/min (ranging from 22 to 76 ml/min).
Blood samples were taken for physician tests.
Hemodialysis patients
105 chronic undergoing hemodialysis patients with no
residual renal function and with no diuresis were
enrolled. They came from two dialytic metropolitan
centers, under the care of our medical staff. The mean
age was 68 years (ranging from 28 to 77 years). Blood
samples were taken for physician tests. The RT and HD
patients were divided into three groups including
patients from 28 to 44 years, 45 to 60 years and 61 to
77 years.
Control group
The control group consisted of 105 healthy people
whose mean age was 58 years (ranging from 26 to
70 years). These healthy subjects were divided into three
groups including subjects from 26 to 40 years, 41 to
55 years and 56 to 70 years.
Simkania detection
Patients Sera were collected from the 105 RT and from
the 105 HD and tested for the presence of IgA and/or
IgG to S. negevensis. As controls, sera from 105 healthy
subjects were used. Six months after the collection of
the first serum sample, a second serum sample was
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collected from ten patients belonging to each of the
two groups, including all patients presenting IgA and 8
patients presenting high IgG titres against S. negeven-
sis. However, only one sample was collected from con-
trols, as no IgA against S. negevensis was detected in
these healthy subjects. S. negevensis Z reference strain
(American Type Culture Collection VR-1471) was cul-
tured in LLC-MK2 cells [18] and Simkania infectious
elementary bodies (EBs) were purified by use of
sucrose gradients [19]. Serum antibodies to S. negeven-
sis EBs were detected by a homemade ELISA
performed according to the Kahane’s protocol [20].
Microtiter plates were coated overnight at 4 °C with
100 Ol of EBs at the concentration of 1 Og/ml in
0.05 M carbonatebicarbonate buffer pH 9.6 and then
blocked and rinsed four times with Tween 20 PBS
(PBST) pH 7.4. Serum samples, diluted 1:100 in PBS-T
supplemented with 5% bovine serum albumin in vol-
umes of 100 Ol per well, were assayed in duplicate and
incubated for 1 h at room temperature. Each plate
assayed included replicate dilutions of two reference
sera with known activity. Contents of the plates were
then removed and replaced with 100 Ol of 6 M urea
for 15 min. After four washes with PBS-T the plates
were incubated with a 1:500 dilution of horseradish
peroxidase (HRP) conjugated antibody anti-human IgG
or IgA (Dako, Denmark), depending on the antibody
immunoglobulin class to be detected. After incubation
for 60 min at room temperature, the plates were
washed and the tetramethylbenzidine substrate (TMB)
(Thermo Scientific, Meridian, USA) was added. After
incubation at room temperature for 10 min, the reac-
tion was stopped by adding 3 M NaOH and the plates
were read at a wavelength of 450 nm, against a refer-
ence wavelength of 630 nm. A positive sample was de-
fined as a sample that yielded an OD450 value of at
least two standard deviations above the mean of 20
negative samples. Positive sera were tested by serial di-
lutions to detect their antibody titre.
Water
A total of 4 water samples were collected from HD tap
water in the same center in two different occasions: two
samples from tap sited before specific water treatment
of disinfection and two samples from tap sited after the
specific treatment of disinfection. The presence of S.
negevensis in the water samples was detected as previ-
ously described [17].
Statistical analysis
Kruskal-Wallis test was used in the statistical analysis of
the data: P values < 0.05 were considered statistically
significant.
Results
IgG and IgA response to S. negevensis detected by ELISA
are shown in Table 1. IgG positive sera showed titres ran-
ging from 100 to 800 and IgA positive sera from 100 to
400. All patient sera positive for IgA were also positive for
IgG against S. negevensis.
Control group
The prevalence of IgG antibodies to S. negevensis was
30% (32/105) in sera of the healthy subjects and no
specific IgA were detected in these sera.
RT patients
The prevalence of IgG antibodies to S. negevensis was 9%
(10/105) in sera of kidney transplant recipients. Specific
IgA were detected in 3% (3/105) of the sera of RT patients.
The second serum sample, collected from the RT S.
negevensis positive patients, six months after the collection
of the first sample, did not show any significant difference
related to the presence and titre of antibodies to S. nege-
vensis. The average value of the number of leukocytes was
6.040/mmc (ranging from 2.000 to 13.000) in patients with
no antibody to S. negevensis versus 7.290/mmc (ranging
from 6.000 to 11.000) in patients serologically positive
against S. negevensis (p < 0.043). No statistically significant
results were found for other tests, even if the index of non-
specific inflammation VES was consistently with higher
values in the positive than in the negative patients
(Table 2).
HD patients
The prevalence of IgG antibodies to S. negevensis was
22% (23/105) in patients undergoing chronic
hemodialysis. Specific IgA were detected in 9% (9/105)
of the sera of HD patients. The second serum sample,
collected from HD S. negevensis positive patients six
months after the collection of the first sample, did not
show any significant difference related to the presence
and titre of antibodies to S. negevensis. In this popula-
tion there is no difference statistically significant de-
tectable for all physician tests between seronegative and
seropositive patients against S. negevensis, even if the
specific and non-specific inflammation tests as VES,
PCR, leukocytes and neutrophils were consistently with
Table 1 IgG and IgA antibodies to S. negevensis in adult
patients by ELISA technique in sera
IgG IgA
Kidney transplant recipients 10/105 (9) 3/105 (3)
Hemodyalisis patients 23/105 (22) 9/105 (9)
Healthy subjects 32/105 (30) 0/105 (0)
Data are presented as N° of ELISA positive sera/N° of sera tested (%)
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higher values in the seropositive than in the seronega-
tive patients (Table 3).
HD and RT patients
When HD and RT patients are considered together, ESR
median value in S. negevensis seronegative patients was
25 (ranging from 2 to 84) in comparison to the mean
value of 39 (ranging from 8 to 101) in S. negevensis sero-
positive patients (p < 0.037). The mean value of leuko-
cytes number was 6.090/mmc (ranging from 2.000 to
14.000) in patients serologically negative against S. nege-
vensis versus 7.290/mmc (ranging from 3000 to 23000)
in seropositive patients (p < 0.038). The average number
of neutrophils was 3420 (ranging from 1.000 to 9.000) in
patients that showed no antibody to S. negevensis in
comparison to 4.500/mmc (ranging from 2.000 to
15.000) in patients that presented IgA and/or IgG anti-
bodies to S. negevensis (p < 0.018) (Table 4).
Hemodialysis waters
S. negevensis was isolated in all water samples ana-
lyzed: both from tap sited before specific water treat-
ment and from tap sited after the specific treatment of
disinfection.
Clinical investigation
The Kruskall-Wallis test showed no correlation for dis-
eases such as gastroenteric disorders, cardiovascular
Table 2 Blood tests in Renal Transplant Patients with IgA or/and IgG antibodies to S. negevensis positive compared to those IgA or/
and IgG antibodies negative
RT
patients
S. negevensis Kruskal-Wallis,
p-valueNegative Positive
Mean Median Min Max Mean Median Min Max
Hemoglobin 12.49 12.40 8 16 12.60 12.40 11 15 n.s.
GOT 16.87 16.00 6 53 14.25 14.50 9 18 n.s.
GPT 14.91 12.50 4 53 11.25 10.00 6 26 n.s.
ESR 19.95 15.00 2 63 30.40 34.00 8 51 n.s.
CRP 1.54 0.77 0.2 9.6 1.4 0.9 0.2 8.9 n.s.
Leukocytes 6.43 6.04 2 13 7.54 7.29 6 11 0.043
Neutrophils 3.79 3.54 1 9 4.75 4.73 3 7 n.s.
Lymphocytes 1.80 1.68 1 4 1.87 1.47 1 4 n.s.
Monocytes 0.48 0.47 0.2 1 0.48 0.49 0.2 1 n.s.
Eosinophils 0.15 0.1 0.1 9.5 0.17 0.18 0.1 8.1 n.s.
GOT glutamic oxaloacetic transaminase (mg/dl), GPT glutamic pyruvic transaminase (mg/dl), ESR erythrocyte sedimentation rate, CRP C-reactive proteine (mg/l). Hemoglobin
values are presented as g/dl. Leukocytes, Neutrophils, Lymphocytes, Monocytes and Eosinophil values are presented as mg/dl
Table 3 Blood tests in Hemodialysis Patients with IgA or/and IgG antibodies to S. negevensis positive compared to those IgA or/and
IgG antibodies negative
HD
patients
S. negevensis Kruskal
Wallis, p-valueNegative Positive
Mean Median Min Max Mean Median Min Max
Hemoglobin 9.68 10.15 8 14.06 10.18 9.85 8 13 n.s.
GOT 17.37 12.00 4 140 13 11 6 29 n.s.
GPT 14.05 12.00 3 64 12.45 9 2 33 n.s.
ESR 40.28 37.50 2 84 48.9 47 25 101 n.s.
CRP 1.34 0.67 0.1 3.6 1.6 0.78 0.1 6 n.s.
Leukocites 6.31 6.18 2 14 8.28 6.94 3 23 n.s.
Neutrophils 3.57 3.30 1 9 5.25 4.26 2 15 n.s.
Lymphocytes 1.56 1.17 1 4 1.51 1.50 1 3 n.s.
Monocytes 0.44 0.45 0.2 1 0.43 0.43 0.2 1 n.s.
Eosinophils 0.25 0.16 0.1 1 0.28 0.19 0.1 1 n.s.
GOT glutamic oxaloacetic transaminase (mg/dl), GPT glutamic pyruvic transaminase (mg/dl), ESR erythrocyte sedimentation rate, CRP C-reactive proteine (mg/l). Hemoglobin
values are presented as g/dl. Leukocytes, Neutrophils, Lymphocytes, Monocytes and Eosinophil values are presented as mg/dl
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events or respiratory diseases between patients present-
ing IgA and/or IgG to S. negevensis, in comparison to
seronegative HD and RT patients.
Discussion
The present investigation evaluates for the first time
the evidence of S. negevensis infection in two different
populations: a cohort of RT patients and a cohort of
HD patients. S. negevensis can induce different types of
infection (active, persistent, cryptic) and it can affect
respiratory epithelial cells, gastrointestinal tract, geni-
tal tract and endothelial cells, as demonstrated by in
vitro studies [14]. S. negevensis virulence mechanisms
may be modified inside the host cell by exchanging
genetic material with other amoeba-resisting micro-
organism and develop virulence mechanisms that make
Simkania able to survive and grow in human macro-
phages [21, 22].
RT patients
S. negevensis IgA response was very low in the RT pa-
tients (overlapping to the complete absence of specific
IgA highlighted in the general population) compared
to the relative high presence of specific IgA highlighted
in the HD population. At the same time, IgG seroposi-
tive appeared very low in the RT patients compared
with the higher seroprevalence of specific IgG in the
HD patients and in the healthy subjects. Therefore, we
can speculate that immunosuppressive compulsory
treatment, does not represent a risk factor for S. nege-
vensis infection. Increase of leukocytes in patients
serologically positive against S. negevensis is not a
speculative results. At our knowledge, there are no re-
ports regarding the association of S. negevensis with
kidney transplant rejection, as for lung transplantation
[15].
HD patients
Higher prevalence of IgA to S. negevensis detected in
the HD patients, in comparison with the RT patients
and the healthy population, was unexpected. S. nege-
vensis is a ubiquitous microorganism and aquatic envi-
ronments involved as source of infection for humans,
because of the large diffusion of the natural protozoan
hosts in water habitats. To our knowledge, few re-
searchers investigated the occurrence of Simkania in
water environments, obtaining very different results in
terms of frequency of detection [16, 23]. Our recent
investigation detected the occurrence of S. negevensis
in chlorinated water samples collected from swimming
pool facilities, examining those classified as spa plants
where a high water temperature (32–36 °C) was
present [17]. In addition, samples from domestic water
supplies were tested. S. negevensis was isolated in spa
water and subsequently identified by PCR. Also the
presence of S. negevensis in swimming pool water
seems much higher compared to that of Legionella
which has never been isolated from samples of inlet
and pool water. This is probably due to the higher re-
sistance of S. negevensis to the greater chlorine con-
centration in swimming pool waters, confirming that
chlorine did not prevent, at the concentrations recom-
mended for swimming pools, the survival and growth
of Simkania. Moreover, S. negevensis was detected both
in cold and hot water samples of the domestic water
systems, while Legionella was isolated only from the
hot water delivered from the showers. The HD patients
represent obviously the cohort most exposed to water.
Table 4 Blood tests in all patients (RT patients + HD patients) with IgA or/and IgG antibodies to S. negevensis positive compared to
those IgA or/and IgG antibodies negative
HD and RT
patients
S. negevensis Kruskal-Wallis,
p-valueNegative Positive
Mean Median Min Max Mean Median Min Max
Hemoglobin 11.21 11.80 8 36.060 11.15 11.15 8 15 n.s.
GOT 17.04 15.00 4 140 13.53 13.00 6 29 n.s.
GPT 14.61 12.00 3 64 11.95 10.00 2 33 n.s.
ESR 29.84 25.00 2 84 42.73 39.00 8 101 0.037
CRP 0.59 0.30 0.1 3.6 1.05 0.33 0.1 6 n.s.
Leukocytes 6.39 6.09 2 14 7.98 7.29 3 23 0.038
Neutrophils 3.71 3.42 1 9 5.05 4.50 2 15 0.018
Lymphocytes 1.72 1.47 1 4 1.66 1.47 1 4 n.s.
Monocytes 0.47 0.45 0.1 1 0.45 0.45 0.1 1 n.s.
Eosinophils 0.25 0.14 0.1 9.5 0.23 0.18 0.1 1 n.s.
GOT glutamic oxaloacetic transaminase (mg/dl), GPT glutamic pyruvic transaminase (mg/dl), ESR erythrocyte sedimentation rate, CRP C-reactive proteine (mg/l). Hemoglobin
values are presented as g/dl. Leukocytes, Neutrophils, Lymphocytes, Monocytes and Eosinophil values are presented as mg/dl
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In the present investigation, it is surprising to note that
S. negevensis was isolated in all water samples col-
lected, both before and after specific disinfection treat-
ment of the HD fluid and that the forced continuous
contact of the HD subjects with the treated water
could be a constant source of infection. The similarity
between the data of the second serum samples and the
first samples collected from S. negevensis positive pa-
tients could be due to this fact. The Italian National
Society of Nephrology has promoted the development
of specific Guidelines for dialysis fluids. An optimal
water treatment system should include tap water pre-
treatment and a double reverse osmosis process. Every
component of the system, including the delivery of the
treated water to the dialysis machines, should prevent
microbiological contamination of the fluid. Regular chem-
ical and microbiological tests and a regular disinfection of
the system are necessary. Treated tap water used to pre-
pare dialysis fluid should be within the limits suggested by
the European Pharmacopoeia for the water treatment sys-
tem inlet and the reverse osmosis outlet. In addition di-
alysate, concentrate and infusion fluids must comply with
the specific Pharmacopoeia limits. Frequently analysis on
microbiological purity in dialysis fluid is a fundamental
pre-requisite for dialysis quality. All Dialysis Unit Care
should aim, as a matter, of course, to obtain an “ultra-
pure” dialysate (microbial count <0.1 UFC/mL, endotoxins
<0.03 U/mL). The two hemodialysis centers of the present
study follow the guidelines of the Italian Society of Neph-
rology [24, 25]. Our findings, however, suggest that the
water treatment system is not able to purify the tap water
from the S. negevensis contamination and that treated
water used in hemodialysis may be involved as a possible
source of S. negevensis infection, thus explaining the
higher prevalence of S. negevensis in the HD patients in
comparison with RT patients. Mostly important, the
forced continuous contact of the HD subjects with S.
negevensis could represent one of the several factors, not
fully known, implicated in the uremic inflammation. In-
flammation and end-stage renal disease are already an old
and intimately related couple. During the last decades,
there has been much progress in elucidating the molecular
mechanisms that lead to inflammatory reactions. More-
over, we have also learnt a lot concerning the charac-
teristic inflammatory profile of the HD patients, which
results from both retention of inflammatory mediators
and increased tissue production. It is largely recog-
nized that persistent inflammation can perturbate bone
homeostasis, thus triggering vascular and arterial calci-
fication, main predictors of cardiovascular mortality in
HD population [26, 27]. Plenty of data exist on the dir-
ect involvement of the HD procedure on inflammation:
the interaction of circulating monocytes with non-
biocompatible membranes, the blood contact with
non-sterile dialysate solution [28], the use of un-pure
dialysate [29], the extent of convective transport, and
the frequency and duration of dialysis [30] also may
contribute to the inflammatory process. Even more re-
cent studies have reported the possibility that infec-
tious agents can trigger a cascade of biochemical and
biological reactions, leading to inflammation. In par-
ticular, microorganisms, such as Chlamydia pneumo-
niae, have been implicated as causative or contributory
factors, being associated with atherosclerosis progres-
sion [31–33]. Then S. negevensis, belonging to the
family Simkaniaceae in the order Chlamydiales, could
continously trigger the cascade of reactions, leading to
systemic inflammation typical of HD population.
Moreover, S. negevensis, just because similarly to Chla-
mydiae, is sensitive to tetracyclines and macrolides
while ampicillin, penicillin G, bacitracin, cyclosporine
and fluoroquinolones are not active against the micro-
organism [34]. The patients selected in the present
study, in particular the HD patients, are generally
treated with quinolone or cephalosporins as a non spe-
cific therapy in suspected infectious events (athero-
venous fistula inflammation, suspect central venous
catheter infection, non-specific gastric disorders,
reported urinary tract disorders) since a susceptibility
test indicating a specific therapy is rarely available in
this infectious events. Therefore, our patients do not
generally take a correct therapy for S. negevensis.
About clinical involvement of S. negevensis infection,
previous evidence indicates a possible role in respira-
tory tract infections and S. negevensis DNA was found
in cardiovascular system, in particular S. negevensis
genome sequences were amplified from sections of ca-
rotid artery tissue [35]. Moreover, some recent data
suggest that the microorganism could be involved in
non-specific gastroenteric symptoms [18]. In patients
of the present study, detection of specific antibodies to
S. negevensis did not show any association with
respiratory diseases, gastroenteric disorders and/or
cardiovascular events.
Conclusion
Our study detected for the first time the occurrence of
S. negevensis in HD and the RT patients. Unexpectedly
we detected a higher IgA seroprevalence against S.
negevensis in HD patients, than in RT. Furthermore,
our findings suggest that water used in hemodialysis
could be one of the possible sources of S. negevensis
infection, without clinical involvement risk for pa-
tients. Further research are required to investigate the
real role of water used in HD and to investigate the hy-
pothesized role of S. negevensis as a trigger of systemic
inflammation in HD population.
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